Topoisomerase II inhibitor
This page covers all Topoisomerase II inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Topoisomerase II.
Targets
Marketed (3)
- Etoposide (ET) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Oncology
Etoposide is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA breaks and cell death in rapidly dividing cells. - VP-16 · PETHEMA Foundation · Oncology
VP-16 (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death. - ETO · Italian Sarcoma Group · Oncology
ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death.
Phase 3 pipeline (1)
- Etoposide (VP-16) · The University of Hong Kong · Oncology
Etoposide is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA breaks and cancer cell death.
Phase 2 pipeline (2)
- Amonafide L-Malate · Xanthus Pharmaceuticals, Inc. · Oncology
Amonafide L-Malate is a quinazoline derivative that intercalates DNA, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells. - 4-Demethyl-4-cholestryloxycarbonylpenclomedine · DEKK-TEC, Inc. · Oncology
4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II.